| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Désirée van der Heijde | Q47262835 |
| P2093 | author name string | K Visser | |
| D M F M van der Heijde | |||
| P433 | issue | 6 | |
| P921 | main subject | methotrexate | Q422232 |
| psoriatic arthritis | Q511097 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 1017-1025 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | Clinical and Experimental Rheumatology | Q15759225 |
| P1476 | title | Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature | |
| P478 | volume | 27 |
| Q34770054 | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers |
| Q57817317 | Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study |
| Q89745202 | Adverse Effects of Low-Dose Methotrexate: A Randomized Trial |
| Q34253312 | Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. |
| Q36758324 | Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend |
| Q52640450 | Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. |
| Q28485164 | Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice |
| Q33955217 | Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record |
| Q40298171 | Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study |
| Q37148784 | Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics |
| Q36633267 | Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate |
| Q37670283 | Liver involvement in patients with systemic autoimmune diseases |
| Q90222764 | Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice |
| Q51320020 | Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. |
| Q97528006 | Methotrexate-associated reversible liver atrophy in a patient with rheumatoid arthritis |
| Q58708624 | Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment |
| Q26995202 | Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review |
| Q35236926 | Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis |
| Q91714782 | Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery |
| Q41870902 | Preparation and assessment of chitosan-coated superparamagnetic Fe3O4 nanoparticles for controlled delivery of methotrexate |
| Q64055048 | Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2 |
| Q34153004 | Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes |
| Q39839858 | Reversal of intestinal failure-associated liver disease (IFALD): emphasis on its multifactorial nature |
| Q46375268 | Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy |
| Q42376342 | Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials |
| Q42363647 | Risk of liver disease in methotrexate treated patients |
| Q35809610 | Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study |
| Q40182074 | Severe hyperferritinemia--a clue for severe hepatitis in a patient with adult-onset Still's disease |
| Q38357969 | The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review. |
| Q38267703 | Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? |
Search more.